Skip to content
- NOA-25/GliProPh-Trial (randomized study comparing proton versus photon radiation therapy for gliomas)
- STUDY STATUS: active
- NOA-24/MecMeth-Trial (phase 1/2 study of combined therapy with meclofenamate and temozolozomide in the first recurrence of MGMT-methylated glioblastoma)
- STUDY STATUS: active
- NOA-23/PersoMed-I-Trial (personalized risk-adapted therapy in post-pubertal and adult patients with newly diagnosed medulloblastoma)
- STUDY STATUS: active
- NOA-22/RIT-GBM-Trial (Phase 1 study to determine the maximum tolerated dose and patient-specific dosimetry of fractionated intracavitary radioimmunotherapy with Lu-177-labeled 6A10-Fab-Fragments in patients with glioblastoma after standard treatment)
- STUDY STATUS: active
- NOA-21/AMPLIFY-NEOVAC-Trial
- STUDY STATUS: active
- NOA-20/N2M2-Trial (umbrella protocol for phase 1/2a studies with molecularly coordinated targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation)
- STUDY STATUS: active
- NOA-19-Trial (retest reliability and localization-dependent sensitivity of neurocognitive testing in newly diagnosed glioblastoma - Re-Cog-GBM-L)
- STUDY STATUS: completed
- NOA-18/Improve-Codel (improvement of functional results in newly diagnosed glioma grade 2/3 with co-deletion of 1p/19q)
- STUDY STATUS: active
- NOA-17/GlioCave-Trial (a phase 2 study on adjuvant stereotactic fractionated radiotherapy of the resection cavity in recurrent glioblastoma)
- STUDY STATUS: completed
- NOA-16-Trial (targeted treatment of IDH1-R132H in WHO grade 3/4 gliomas with IDH1-R132H mutation by a peptide vaccine)
- STUDY STATUS: completed
- NOA-14/HIPPORAD-Trial (prospective, randomized, multicenter phase 2 study on whole-brain irradiation with hippocampal sparing and dose escalation for metastases)
- STUDY STATUS: completed
- NOA-13-Trial (prospective observational study on chemotherapy in non-specifically pre-treated patients with primary CNS lymphoma)
- STUDY STATUS: active
